Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMCOpen access

Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention

Zhang J., Zhang M., Ren X., Li M., Zhu Y., Shou D.

Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Int J Nanomedicine (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41852781
PMCID
PMC12994405
DOI
10.2147/ijn.s582197
Citations
1

Abstract (original English)

Exosome-mediated intercellular communication has become a critical mechanism in the pathogenesis, progression, and regenerative repair of orthopedic diseases. By delivering bioactive molecules, exosomes dynamically regulate bone remodeling, cartilage homeostasis, and inflammatory responses-processes that are commonly disrupted in conditions such as osteoporosis, osteoarthritis, and bone non-union. Current therapeutic approaches often fail to achieve complete tissue repair or reverse disease progression, representing a major clinical challenge in orthopedics. This systematic review examines how exosome secretion, cargo loading, and cellular uptake are modulated by physical, chemical, biological, and pharmacological factors, thereby influencing disease progression and tissue repair. Furthermore, we evaluate the translational potential of engineered exosomes as targeted therapeutic strategies and analyze the dual dilemmas currently faced in exosome research and clinical translation: on one hand, exosomes themselves encounter technical bottlenecks such as standardization of isolation, drug-loading efficiency, large-scale production, and targeted delivery; on the other hand, their clinical application remains limited by unclear in vivo metabolic mechanisms, lack of efficacy evaluation systems, and insufficient clinical validation. Overcoming these challenges will be essential to adv

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
AnimalsHumansBone DiseasesDrug Delivery SystemsCell CommunicationExosomes

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research